文献速递核素与放射性配体治疗骨显像与常规 SPECT放射性药物与辐射防护

镥-177/锕-225标记PSMA放射性配体治疗前使用[99mTc]Tc-抗粒细胞抗体显像预测骨髓储备

[99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-06

研究纳入10例[18F]F-PSMA PET/CT显示广泛骨转移的转移性去势抵抗性前列腺癌患者,行[99mTc]Tc-抗粒细胞抗体显像评估骨髓储备与放射性配体治疗资格。9/10(90.0%)患者未见存活骨髓与PSMA阳性转移灶明显共定位。随访实验室结果较基线无显著变化(p > 0.05)。

要点

  • 10例广泛骨转移mCRPC患者中9/10(90.0%)未见存活骨髓与PSMA阳性转移灶明显共定位。
  • 无显著共定位者接受[177Lu]Lu-PSMA或[225Ac]Ac-PSMA治疗,随访实验室结果较基线无显著变化(p > 0.05)。
  • 作者认为空间不匹配与无显著骨髓毒性相关,高度重叠可能增加风险,但目前无固定阈值,该方法应视为复杂病例的补充工具。

核心结论

  • [99mTc]Tc-抗粒细胞抗体显像可能支持广泛骨转移患者的骨髓储备评估。
  • 空间不匹配与无显著骨髓毒性相关,而高度重叠可能增加风险,但目前无固定阈值,该方法应视为复杂病例的补充工具,未来研究需定义关键骨髓体积。

研究设计与样本

  • 研究纳入10例[18F]F-PSMA PET/CT显示广泛骨肿瘤负荷的mCRPC患者,行[99mTc]Tc-抗粒细胞抗体显像评估骨髓储备与RLT资格(间隔26.6 ± 18.5天)。

主要发现

  • 9/10(90.0%)患者未见存活骨髓与PSMA阳性转移灶明显共定位。
  • 另2例患者因禁忌证被排除RLT;其余7例中2/7(28.6%)接受[177Lu]Lu-PSMA治疗,2/7(28.6%)接受[225Ac]Ac-PSMA治疗,2/7(28.6%)接受[225Ac]Ac-[177Lu]Lu-PSMA治疗,1/7(14.3%)接受单周期[177Lu]Lu-PSMA后序贯[225Ac]Ac-PSMA治疗。
  • 随访实验室结果较基线无显著变化(p > 0.05)。

关键数值与推荐

  • 无显著共定位患者接受[177Lu]Lu-PSMA或[225Ac]Ac-PSMA治疗,治疗前后及周期间进行实验室监测。
  • 目前无固定阈值;该方法应视为复杂病例的补充工具,未来研究需定义关键骨髓体积。

临床怎么用

  • 作者认为[99mTc]Tc-抗粒细胞抗体显像可能支持广泛骨转移患者的骨髓储备评估,空间不匹配与无显著骨髓毒性相关,而高度重叠可能增加风险。
  • 作者指出目前无固定阈值,该方法应视为复杂病例的补充工具,未来研究需定义关键骨髓体积。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radioligand therapy (RLT) targeting PSMA (prostate-specific membrane antigen) has transformed the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, bone marrow depletion remains a common side effect, particularly in patients with extensive bone metastases or prior myelotoxic therapies. This study evaluated [99mTc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve to guide myelotoxic treatment decisions. METHODS: Ten mCRPC patients with extensive osseous tumor load on [18F]F-PSMA PET/CT underwent [99mTc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve and RLT eligibility (interval: 26.6 ± 18.5 days). Visual comparison of both modalities evaluated tumor-bone marrow overlap. Patients without significant co-localization received RLT ([177Lu]Lu-PSMA or [225Ac]Ac-PSMA) with laboratory monitoring before and between the cycles. RESULTS: No significant co-localization between viable bone marrow and PSMA-positive metastases was observed in 9/10 (90.0%) patients. Two other patients were excluded from RLT due to contraindications. Of the remaining seven patients, 2/7 (28.6%) underwent subsequent [177Lu]Lu-PSMA therapy, 2/7 (28.6%) [225Ac]Ac-PSMA therapy and 2/7 (28.6%) [225Ac]Ac-[177Lu]Lu-PSMA therapy. 1/7 (14.3%) received a single cycle of [177Lu]Lu-PSMA, which was then followed by [225Ac]Ac-PSMA therapy. Follow-up laboratory results showed no significant changes from baseline (p > 0.05). CONCLUSION: [99mTc]Tc-antigranulocyte scintigraphy may support the assessment of bone marrow reserve in patients with extensive bone metastases. Spatial mismatch was associated with no significant myelotoxicity, whereas high congruence may increase the risk. No fixed thresholds currently exist; thus, this method should be regarded as a supplementary tool in complex cases and future studies are needed to define the critical bone marrow volume.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kunte SC, Delker A, Holzgreve A, et al. [99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40325260. doi:10.1007/s00259-025-07319-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。